查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2040886

泌尿系統疾病治療市場預測至2034年—按類型、治療方法、診斷、最終用戶和地區分類的全球分析

Uropathy Treatment Market Forecasts to 2034 - Global Analysis By Type (Obstructive Uropathy, Functional Uropathy, Inflammatory Uropathy, Congenital Uropathy and Urological Cancers), Treatment Type, Diagnosis, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球泌尿系統疾病治療市場規模將達到 52.4 億美元，並在預測期內以 6.0% 的複合年成長率成長，到 2034 年將達到 83.5 億美元。

泌尿系統疾病是指影響泌尿系統（包括腎臟、輸尿管、膀胱和尿道）的多種疾病。泌尿系統疾病的治療取決於特定病因和症狀的嚴重程度。創新不僅體現在手術等治療方法上。利用先進的影像技術（例如3D前列腺磁振造影）進行早期診斷，可以實現及時干預。個人化醫療根據個體的基因和分子特徵制定個人化的治療方案，從而為更有效、更有針對性的療法鋪路。

根據發表在《泌尿外科進展》雜誌上的一項研究，腎結石是一種日益嚴重的泌尿系統疾病，影響全球約15%的人口。雖然任何年齡都可能發生腎結石，但在20至49歲的男性中，其發生率高於女性。

泌尿系統疾病發生率上升

隨著尿道感染、腎結石和前列腺疾病等疾病的發病率持續上升，對有效且創新的治療方法的需求日益成長。患者數量的激增不僅凸顯了對先進治療方案的迫切需求，也推動了泌尿系統疾病治療領域的研究與發展。因此，在公眾意識提高和教育力度加強的推動下，人們對泌尿系統醫療保健的關注度不斷提升，這進一步加速了市場擴張，並為診斷、藥物和醫療干預等方面的進步創造了機遇，以滿足與泌尿系統疾病相關的日益成長的醫療保健需求。

合格醫護人員短缺

由於泌尿系統疾病需要非常規治療方法，因此正確的治療和監測需要專業的知識和技能。合格人員（包括泌尿系統和接受泌尿系統專科培訓的醫護人員）的短缺導致診斷延誤、治療不足以及患者照護品質下降。此外，這種短缺還增加了現有醫護人員的工作量，可能導致職業倦怠和護理品質下降，從而阻礙市場成長。

人們對泌尿系統健康的認知不斷提高，各種治療方案也日益普及。

隨著人們對泌尿系統疾病及其潛在影響的了解不斷加深，預防和早期檢測的重要性日益凸顯。這一趨勢促使患者篩檢、諮詢和主動就醫行為激增，從而對泌尿科治療的需求產生了積極影響。這不僅滿足了個人偏好，也促進了個人化治療方案的製定，提高了患者的整體滿意度和治療順從性。這種意識的提高，加上治療選擇的日益豐富，共同推動了市場成長。

缺乏標準化的規程和指南

泌尿系統疾病治療缺乏統一標準，導致治療方案、劑量和應用方法存在差異，引發人們對安全性、有效性和可重複性的擔憂。這種不統一性使醫療專業人員感到不確定性，從而猶豫是否將泌尿系統治療納入常規臨床實踐。患者也可能因為認為缺乏標準化和安全性保障而對泌尿系統治療有所顧慮。為了克服這些障礙並建立市場信心，制定和推廣標準化方案至關重要。

新冠疫情的感染疾病

醫療系統和資源承受前所未有的壓力，加之封鎖和旅行限制，導致泌尿系統手術延誤，非緊急情況下的就診量減少。許多醫療機構已將資源轉移到應對新冠肺炎病例激增，影響了泌尿系統治療的發展。此外，疫情帶來的經濟影響也改變了患者的就醫選擇，一些患者由於經濟不不確定性而推遲了擇期泌尿系統治療，阻礙了市場成長。

在預測期內，阻塞性泌尿道疾病預計將成為最大的組成部分。

由於慢性阻塞性肺病（COPD）患者會出現尿流受阻，並可能引發腎損傷和感染疾病等多種併發症，因此預計該疾病領域將呈現良好的成長前景。泌尿道疾病治療市場對COPD介入措施的需求可能會增加，包括手術、導尿和藥物治療。此外，針對COPD根本病因的研究和開發活動可能會激增，從而有望開發出標靶治療，進而推動市場成長。

在預測期內，尿液檢查領域預計將呈現最高的複合年成長率。

在預測期內，尿液檢查領域預計將呈現最高的複合年成長率。這是因為尿液檢體分析能夠幫助醫療專業人員檢測各種異常情況，例如感染疾病、腎臟疾病和代謝紊亂，進而影響泌尿系統疾病的治療策略。準確的尿液檢查結果有助於診斷泌尿系統疾病的根本原因，並制定個人化且有效的治療方案。此外，尿液檢查還有助於監測和評估治療效果，並透過根據患者反應調整治療方案來推動市場成長。

市佔率最大的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率。這是因為該地區泌尿系統疾病（如腎結石、良性前列腺增生和尿失禁）的發生率不斷上升，推動了對治療方法的需求。此外，微創手術、機器人輔助手術和先進的影像技術正在改變泌尿系統的治療方式，提供更精準、更有效的治療，並縮短患者的恢復時間，從而推動該地區的市場成長。

複合年成長率最高的地區：

預計北美地區在預測期內將呈現最高的複合年成長率。這主要是由於腎結石、尿道感染和前列腺癌等疾病在北美地區的發生率不斷上升。而人口老化、久坐的生活方式和日益嚴重的肥胖問題等因素是造成此現象的主要原因。此外，近年來泌尿系統領域取得了顯著進展，包括微創手術、機器人手術和個人化醫療等技術的進步。這些進步透過改善患者預後和縮短復原時間，推動了市場成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球泌尿系統疾病治療市場：依類型分類

  • 阻塞性泌尿系統疾病
  • 功能性泌尿系統疾病
  • 發炎性泌尿道疾病
  • 先天性泌尿系統畸形
  • 泌尿系統癌症

第6章 全球泌尿系統疾病治療市場：依治療類型分類

  • 藥物治療
    • 抗生素
    • 止痛藥
    • α受體阻斷劑或α還原酶抑制劑
    • 荷爾蒙療法
  • 外科手術技巧
    • 膀胱鏡檢查
    • 體外震波碎石術
    • 輸尿管鏡檢查
    • 支架置入
  • 生活方式改善

第7章 全球泌尿系統疾病治療市場：依診斷分類

  • 尿液檢查
  • 驗血
  • 影像檢查

第8章 全球泌尿系統疾病治療市場：依最終用戶分類

  • 醫院和診所
  • 門診手術中心
  • 其他最終用戶

第9章 全球泌尿系統疾病治療市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Abbott
  • Novartis AG
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Eli Lilly and Company
  • Ionis Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Merck & Co. Inc.
  • GlaxoSmithKline
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Antares Pharma
  • Allergan
  • AstraZeneca
  • Cook Medical
  • Sanofi
  • Olympus Corporation
  • Teleflex Incorporated
  • Argon Medical Devices, Inc
Product Code: SMRC25098

According to Stratistics MRC, the Global Uropathy Treatment Market is accounted for $5.24 billion in 2026 and is expected to reach $8.35 billion by 2034 growing at a CAGR of 6.0% during the forecast period. Uropathy refers to a broad range of conditions affecting the urinary tract, including the kidneys, ureters, bladder, and urethra. Treatment for uropathy depends on the specific underlying cause and severity of the condition. Innovation extends beyond procedures. Early diagnosis through advanced imaging techniques like 3D prostate MRI empowers timely intervention. Personalized medicine tailors treatment plans based on individual genetic and molecular profiles, paving the way for more effective and targeted therapies.

According to a study published in Advances in Urology, Kidney stone disease is an increasing urological disorder of human health which is affecting about 15% of the world population and it affects all age groups but occurs more frequently in men than in women within the age of 20-49 years.

Market Dynamics:

Driver:

Rising incidence of urological conditions

As the prevalence of disorders such as urinary tract infections, kidney stones, and prostate issues continues to rise, there is a heightened demand for effective and innovative treatments. This surge in patient numbers not only underscores the urgent need for advanced therapeutic solutions but also propels research and development efforts within the Uropathy Treatment sector. Thus the increased focus on urological health, fuelled by the rise in awareness and education, further amplifies the market's expansion, creating opportunities for advancements in diagnostics, pharmaceuticals, and medical interventions to cater to the escalating healthcare needs associated with urological conditions.

Restraint:

Shortage of qualified healthcare professionals

Uropathy, as an unconventional treatment, requires specialized knowledge and expertise for proper administration and monitoring. The scarcity of qualified professionals including urologists and healthcare providers with specific training in uropathy, results in delayed diagnosis, inadequate treatment, and compromised patient care. Moreover, the shortage contributes to increased workloads for existing healthcare professionals, potentially leading to burnout and decreased quality of care impeding the market growth.

Opportunity:

Increased awareness of urological health and the availability of various treatment options

As individuals become more informed about urological disorders and their potential consequences, there is a growing emphasis on preventive measures and early detection. This trend has driven a surge in patient screenings, consultations, and proactive healthcare seeking behaviours, positively influencing the demand for uropathy treatments. This not only caters to individual preferences but also promotes personalized treatment plans, enhancing overall patient satisfaction and compliance. The combined effect of heightened awareness and treatment options contributes to the growth of the market

Threat:

Lack of standardized protocols and guidelines

The lack of established norms for uropathy treatments leads to variability in procedures, dosages, and application methods, raising concerns about safety, efficacy, and reproducibility. This inconsistency creates uncertainty among healthcare professionals, making them hesitant to integrate uropathy into routine clinical practices. Patients may be hesitant to explore uropathy treatments due to the perceived lack of standardization and assurance of safety. Developing and promoting standardized protocols are essential for overcoming these obstacles and fostering confidence in the market.

Covid-19 Impact

The unprecedented strain on healthcare systems and resources, coupled with lockdowns and travel restrictions, has led to delays in urological procedures and reduced patient visits for non-emergent conditions. Many healthcare facilities have diverted their focus and resources toward managing the surge in COVID-19 cases, affecting the delivery of uropathy treatments. Moreover, the economic repercussions of the pandemic have influenced patient priorities, with some individuals opting to postpone elective urological treatments due to financial uncertainties hampering the market growth.

The obstructive uropathy segment is expected to be the largest during the forecast period

The obstructive uropathy segment is estimated to have a lucrative growth, as patients with obstructive uropathy may experience impaired urinary flow, leading to various complications such as kidney damage and infections. The market for uropathy treatment may see an increased demand for interventions addressing obstructive uropathy, including surgical procedures, catheterization, and pharmacological treatments. Additionally, the market may witness a surge in research and development efforts focused on addressing the underlying causes of obstructive uropathy, including the development of targeted therapies which encourage in the market growth.

The urinalysis segment is expected to have the highest CAGR during the forecast period

The urinalysis segment is anticipated to witness the highest CAGR growth during the forecast period, because the analysis of urine samples allows healthcare professionals to detect various abnormalities, such as infections, kidney diseases, and metabolic disorders, influencing the course of uropathy treatments. Precise urinalysis results aid in diagnosing the root cause of urological conditions, enabling personalized and effective treatment plans. Furthermore, urinalysis contributes to the monitoring and assessment of treatment efficacy, allowing adjustments based on patient responses boosting the markets growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the prevalence of urological conditions like kidney stones, prostate enlargement, and urinary incontinence increases in this region are fuelling demand for treatment options. Moreover minimally invasive surgeries, robotic-assisted procedures, and advanced imaging technologies are transforming urological care, offering precise and effective treatments with faster recovery times are driving the growth of the market in this region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to Conditions like kidney stones, urinary tract infections (UTIs), and prostate cancer are becoming increasingly common in North America. This is due to factors like aging population, sedentary lifestyles, and rising obesity rates. Moreover, the field of urology has seen significant advancements in recent years, with the development of minimally invasive procedures, robotic surgery, and personalized medicine approaches. These advancements are leading to improved patient outcomes and shorter recovery times thus encouraging the growth of the market.

Key players in the market

Some of the key players in the Uropathy Treatment Market include Abbott, Novartis AG, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Genentech, Inc., Eli Lilly and Company, Ionis Pharmaceuticals, Inc., Pfizer, Inc., Merck & Co. Inc., GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Bayer AG, Antares Pharma, Allergan, AstraZeneca, Cook Medical, Sanofi, Olympus Corporation, Teleflex Incorporated and Argon Medical Devices, Inc

Key Developments:

In January 2024, Abbott announced the first global procedures have been conducted using the company's new Volt(TM) Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib).

In January 2024, Novartis expands production of Pluvicto(TM) with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis. FDA approval of the company's second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond

In October 2023, Novartis confirms unconstrained supply for Pluvicto(R) and continues to significantly expand the number of treatment centers. Novartis is committed to providing a consistent, reliable supply of Pluvicto and making this important medicine readily available to patients.

Types Covered:

  • Obstructive Uropathy
  • Functional Uropathy
  • Inflammatory Uropathy
  • Congenital Uropathy
  • Urological Cancers

Treatment Types Covered:

  • Drug Therapy
  • Surgery Procedures
  • Lifestyle Modification

Diagnosis Covered:

  • Urinalysis
  • Blood Tests
  • Imaging Tests

End Users Covered:

  • Hospitals & Clinics
  • Ambulatory Surgical Centre
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Uropathy Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Obstructive Uropathy
  • 5.3 Functional Uropathy
  • 5.4 Inflammatory Uropathy
  • 5.5 Congenital Uropathy
  • 5.6 Urological Cancers

6 Global Uropathy Treatment Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Drug Therapy
    • 6.2.1 Antibiotics
    • 6.2.2 Pain Relievers
    • 6.2.3 Alpha-Blockers or Alpha-Reductase Inhibitors
    • 6.3.4 Hormone Therapy
  • 6.3 Surgery Procedures
    • 6.3.1 Cystoscopy
    • 6.3.2 Lithotripsy
    • 6.3.3 Ureteroscopy
    • 6.3.4 Stenting
  • 6.4 Lifestyle Modification

7 Global Uropathy Treatment Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 Urinalysis
  • 7.3 Blood Tests
  • 7.4 Imaging Tests

8 Global Uropathy Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Ambulatory Surgical Centre
  • 8.4 Other End Users

9 Global Uropathy Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott
  • 11.2 Novartis AG
  • 11.3 Bristol-Myers Squibb Co.
  • 11.4 F. Hoffmann-La Roche Ltd.
  • 11.5 Genentech, Inc.
  • 11.6 Eli Lilly and Company
  • 11.7 Ionis Pharmaceuticals, Inc.
  • 11.8 Pfizer, Inc.
  • 11.9 Merck & Co. Inc.
  • 11.10 GlaxoSmithKline
  • 11.11 Teva Pharmaceutical Industries Ltd.
  • 11.12 Bayer AG
  • 11.13 Antares Pharma
  • 11.14 Allergan
  • 11.15 AstraZeneca
  • 11.16 Cook Medical
  • 11.17 Sanofi
  • 11.18 Olympus Corporation
  • 11.19 Teleflex Incorporated
  • 11.20 Argon Medical Devices, Inc

List of Tables

  • Table 1 Global Uropathy Treatment Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Uropathy Treatment Market Outlook, By Type (2023-2034) ($MN)
  • Table 3 Global Uropathy Treatment Market Outlook, By Obstructive Uropathy (2023-2034) ($MN)
  • Table 4 Global Uropathy Treatment Market Outlook, By Functional Uropathy (2023-2034) ($MN)
  • Table 5 Global Uropathy Treatment Market Outlook, By Inflammatory Uropathy (2023-2034) ($MN)
  • Table 6 Global Uropathy Treatment Market Outlook, By Congenital Uropathy (2023-2034) ($MN)
  • Table 7 Global Uropathy Treatment Market Outlook, By Urological Cancers (2023-2034) ($MN)
  • Table 8 Global Uropathy Treatment Market Outlook, By Treatment Type (2023-2034) ($MN)
  • Table 9 Global Uropathy Treatment Market Outlook, By Drug Therapy (2023-2034) ($MN)
  • Table 10 Global Uropathy Treatment Market Outlook, By Antibiotics (2023-2034) ($MN)
  • Table 11 Global Uropathy Treatment Market Outlook, By Pain Relievers (2023-2034) ($MN)
  • Table 12 Global Uropathy Treatment Market Outlook, By Alpha-Blockers or Alpha-Reductase Inhibitors (2023-2034) ($MN)
  • Table 13 Global Uropathy Treatment Market Outlook, By Hormone Therapy (2023-2034) ($MN)
  • Table 14 Global Uropathy Treatment Market Outlook, By Surgery Procedures (2023-2034) ($MN)
  • Table 15 Global Uropathy Treatment Market Outlook, By Cystoscopy (2023-2034) ($MN)
  • Table 16 Global Uropathy Treatment Market Outlook, By Lithotripsy (2023-2034) ($MN)
  • Table 17 Global Uropathy Treatment Market Outlook, By Ureteroscopy (2023-2034) ($MN)
  • Table 18 Global Uropathy Treatment Market Outlook, By Stenting (2023-2034) ($MN)
  • Table 19 Global Uropathy Treatment Market Outlook, By Lifestyle Modification (2023-2034) ($MN)
  • Table 20 Global Uropathy Treatment Market Outlook, By Diagnosis (2023-2034) ($MN)
  • Table 21 Global Uropathy Treatment Market Outlook, By Urinalysis (2023-2034) ($MN)
  • Table 22 Global Uropathy Treatment Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 23 Global Uropathy Treatment Market Outlook, By Imaging Tests (2023-2034) ($MN)
  • Table 24 Global Uropathy Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 25 Global Uropathy Treatment Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 26 Global Uropathy Treatment Market Outlook, By Ambulatory Surgical Centre (2023-2034) ($MN)
  • Table 27 Global Uropathy Treatment Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.